Frequently Asked Questions About NeuropAWAY Nerve Support Formula
The only nerve support formula put through a published clinical trial — and the results were published for anyone to check.
NeuropAWAY® isn’t built on borrowed ingredient studies. The finished formula was tested in a peer-reviewed, double-blind, placebo-controlled trial in people living with diabetic nerve pain. Here is exactly what happened.
Pain intensity over 6 weeks
Pain intensity fell 61% over six weeks in the NeuropAWAY group. The placebo group didn’t improve at all — their pain edged slightly higher. Measured the way prescription-drug trials report results, that’s a placebo-adjusted advantage of nearly 5 points on a 10-point pain scale (p<0.001) — several times larger than the gap typically seen with leading nerve-pain medications.
What the trial measured
59 adults with type 2 diabetes and diagnosed diabetic peripheral neuropathy, all on standard metformin care, took NeuropAWAY or a matched placebo for 42 days. Neither participants nor researchers knew which was which until the data were locked.
What’s inside — and why the blend, not just one ingredient
Most nerve supplements lean on a single hero ingredient. NeuropAWAY pairs methylcobalamin (an active B12) with five amino acids and antioxidants chosen to work together. The trial tested this exact combination as a finished product.
Frequently asked questions
Straight answers, drawn directly from the published trial.
Has NeuropAWAY actually been clinically studied?
Yes. NeuropAWAY was tested in a double-blind, randomized, placebo-controlled clinical trial — the most rigorous study design there is — and the results were published in 2023 in the peer-reviewed Journal of Pain Research. Critically, the trial tested the actual finished NeuropAWAY formula, not just its individual ingredients. The full study is openly available to read (PMID: 37020664).
What were the results of the NeuropAWAY clinical trial?
Over six weeks, participants taking NeuropAWAY saw their average pain score fall 61% (from 7.8 to 3.0 on a 10-point scale), while the placebo group did not improve — their pain edged slightly higher. Measured the way prescription-drug trials report results, that is a placebo-adjusted advantage of nearly 5 points on the 10-point scale (p<0.001). By the end of the study, 85% of NeuropAWAY participants had at least a 50% reduction in pain and 93% had at least a 30% reduction — compared with none in the placebo group.
Specific symptoms improved too: burning fell 73%, tingling 66%, numbness 55%, and aching and tightness 76%. Sleep disruption improved 60%, and active vitamin B12 levels nearly doubled.
How quickly does NeuropAWAY work?
In the trial, pain was already significantly lower than placebo within the first 7 days. The effect grew over time, with the largest reduction measured at day 42. Results build with consistent daily use over the full six weeks, so give it time.
How do I take NeuropAWAY to get the results from the study?
In the clinical trial, participants took two capsules about 30 minutes before meals, three times a day — six capsules daily — for the full six weeks. That sustained daily dose is what produced the 61% pain reduction. To reproduce the study results, take it the way the study did: six capsules a day, every day, for at least six weeks. Always follow the directions on your bottle and check with your doctor.
Is NeuropAWAY safe? Are there side effects?
In the trial, no adverse events were reported, and there were no significant changes in participants’ blood counts, liver enzymes, or kidney markers across six weeks. As with any supplement, talk to your doctor before starting — especially if you take prescription medications or have a medical condition.
How is NeuropAWAY different from taking alpha-lipoic acid or B12 on their own?
Single ingredients like alpha-lipoic acid and B12 each have their own research, but NeuropAWAY was designed and tested as a combination — methylcobalamin plus taurine, acetyl-L-carnitine, L-citrulline, beta-alanine, and R-alpha-lipoic acid. The published trial measured the finished blend, so the 61% result reflects the formula as you actually take it, not a single isolated nutrient.
Who was the study done on — is it relevant to me?
The trial enrolled adults aged 40–65 with type 2 diabetes and a confirmed diagnosis of diabetic peripheral neuropathy (diabetic nerve pain), who were on standard diabetes care. If that describes you, the study population is a close match. The trial did not specifically test other causes of neuropathy.
Is NeuropAWAY FDA approved?
NeuropAWAY is a dietary supplement, not a drug, so it is not “FDA approved” — no dietary supplement is. It is manufactured in a GMP-certified facility, and unlike most supplements in this category, the finished formula has been tested in a published, peer-reviewed clinical trial. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Where can I read the full study myself?
The complete study is open-access and free to read. Citation: Cross W, Srivastava S. A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy of a Nerve Support Formula on Neuropathic Pain in Individuals Suffering from Type II Diabetes Mellitus. Journal of Pain Research. 2023;16:1115–1126. doi:10.2147/JPR.S397777. You can find it on PubMed (PMID: 37020664).
Read the trial. Then decide for yourself.
We put our money behind a real study and published the results in full — including what didn’t change. That’s rare in this category, and it’s the whole point.